As of 2025-05-17, the EV/EBITDA ratio of Sorrento Therapeutics Inc (SRNE) is -0.21. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SRNE's latest enterprise value is 73.01 mil USD. SRNE's TTM EBITDA according to its financial statements is -340.66 mil USD. Dividing these 2 quantities gives us the above SRNE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 8.7x - 13.5x | 13.3x |
| Forward P/E multiples | 13.1x - 16.8x | 13.7x |
| Fair Price | (2,291.25) - (2,360.30) | (2,367.20) |
| Upside | -745705.6% - -768176.3% | -770423.3% |
| Date | EV/EBITDA |
| 2025-05-13 | -0.21 |
| 2025-05-12 | -0.21 |
| 2025-05-09 | -0.21 |
| 2025-05-08 | -0.21 |
| 2025-05-07 | -0.21 |
| 2025-05-06 | -0.21 |
| 2025-05-05 | -0.21 |
| 2025-05-02 | -0.21 |
| 2025-05-01 | -0.21 |
| 2025-04-30 | -0.21 |
| 2025-04-29 | -0.21 |
| 2025-04-28 | -0.21 |
| 2025-04-25 | -0.21 |
| 2025-04-24 | -0.21 |
| 2025-04-23 | -0.21 |
| 2025-04-22 | -0.21 |
| 2025-04-21 | -0.21 |
| 2025-04-17 | -0.21 |
| 2025-04-16 | -0.21 |
| 2025-04-15 | -0.21 |
| 2025-04-14 | -0.21 |
| 2025-04-11 | -0.21 |
| 2025-04-10 | -0.21 |
| 2025-04-09 | -0.21 |
| 2025-04-08 | -0.21 |
| 2025-04-07 | -0.21 |
| 2025-04-04 | -0.21 |
| 2025-04-03 | -0.21 |
| 2025-04-02 | -0.21 |
| 2025-04-01 | -0.21 |
| 2025-03-31 | -0.21 |
| 2025-03-28 | -0.21 |
| 2025-03-27 | -0.21 |
| 2025-03-26 | -0.21 |
| 2025-03-25 | -0.21 |
| 2025-03-24 | -0.21 |
| 2025-03-21 | -0.21 |
| 2025-03-20 | -0.21 |
| 2025-03-19 | -0.21 |
| 2025-03-18 | -0.21 |
| 2025-03-17 | -0.21 |
| 2025-03-14 | -0.21 |
| 2025-03-13 | -0.21 |
| 2025-03-12 | -0.21 |
| 2025-03-11 | -0.21 |
| 2025-03-10 | -0.21 |
| 2025-03-07 | -0.21 |
| 2025-03-06 | -0.21 |
| 2025-03-05 | -0.21 |
| 2025-03-04 | -0.21 |